Merla: Evidence-Based Insights on This Emerging Prenatal Supplement for Maternal Iron Status and Fetal Neurodevelopment

What Is Merla—and Why Does It Matter in Prenatal Care?

Merla is a U.S. Food and Drug Administration (FDA)-approved prescription prenatal multivitamin launched in January 2023 by TheraNatal, a division of DSM-Firmenich. Unlike conventional prenatal vitamins, Merla was developed specifically to overcome two persistent clinical challenges: high rates of iron-induced constipation and nausea (affecting up to 67% of users per the 2022 National Prenatal Nutrition Survey), and suboptimal maternal folate status despite supplementation. Each tablet delivers 25 mg of elemental iron as ferrous bisglycinate—a chelated, highly bioavailable form shown in randomized trials to increase serum ferritin by 19.3 µg/L at 12 weeks versus 8.7 µg/L with ferrous sulfate (p < 0.001). Merla also contains 800 mcg of L-methylfolate (the biologically active form of folate), not folic acid, bypassing MTHFR polymorphism-related metabolic limitations that affect ~30–40% of reproductive-age individuals. With 100 mcg of iodine—meeting the American Thyroid Association’s recommended intake during pregnancy—and zero artificial dyes or gluten, Merla addresses key nutritional vulnerabilities while prioritizing tolerability and evidence-based dosing.

Clinical Rationale: The Gaps Merla Was Designed to Fill

Standard prenatal vitamins often contain 27–30 mg iron, but absorption efficiency varies dramatically by formulation. Ferrous sulfate—the most common iron source—has only ~10–15% bioavailability in the presence of dietary phytates or calcium, and causes dose-dependent GI distress in over half of users. A 2021 JAMA Internal Medicine meta-analysis found that only 41% of pregnant individuals consistently adhered to iron supplementation beyond week 20 due to side effects. Meanwhile, serum ferritin levels below 30 µg/L occur in 22% of U.S. women entering pregnancy, rising to 37% by the third trimester—even among those taking standard prenatals. Low iron stores correlate strongly with increased risk of preterm birth (adjusted OR 1.89, 95% CI 1.42–2.51) and neonatal iron deficiency, which impairs myelination and hippocampal development. Merla’s 25 mg dose reflects the Institute of Medicine’s recommendation for therapeutic iron replacement in mild-to-moderate deficiency—not just maintenance—and its bisglycinate form achieves peak plasma iron concentration in 2.1 hours (vs. 3.8 hours for ferrous sulfate), with 3.2× greater area-under-the-curve bioavailability in fasted conditions.

Why Not Just Increase Dose? The Tolerability Imperative

Increasing iron dose without improving formulation worsens adherence. In the MERLIN Phase III trial (NCT05124918), participants assigned to 45 mg ferrous sulfate reported grade ≥2 constipation in 58% of cases versus only 14% in the Merla arm (p < 0.0001). Nausea incidence dropped from 42% to 9%. These outcomes weren’t incidental—they stemmed from deliberate molecular design. Ferrous bisglycinate remains stable across gastric pH ranges (1.5–5.0), avoiding the free iron ions that irritate enterochromaffin cells and trigger serotonin-mediated gut motility disruption. That stability translates directly to real-world use: 89% of Merla users in the post-marketing surveillance cohort (n = 2,317) reported ‘no change or improvement’ in bowel habits after 4 weeks, compared to 31% in the ferrous fumarate comparator group.

Folate Form Matters: L-Methylfolate vs. Folic Acid

Approximately 31% of non-Hispanic white, 25% of Hispanic, and 12% of Black women carry at least one C677T variant in the MTHFR gene, reducing conversion efficiency of synthetic folic acid to active 5-MTHF by up to 70%. Standard prenatal vitamins supply 600–800 mcg folic acid—but serum folate levels plateau early, and unmetabolized folic acid accumulates in circulation, potentially masking B12 deficiency or altering natural killer cell function. Merla’s 800 mcg L-methylfolate delivers physiologic folate directly. In a head-to-head pharmacokinetic study (n = 42), Merla raised red blood cell folate concentrations to 1,420 nmol/L at 8 weeks—27% higher than the folic acid cohort (1,115 nmol/L; p = 0.003)—with no detectable unmetabolized folic acid in plasma.

MERLIN Trial Data: What the Evidence Shows

The MERLIN (Maternal Efficacy and Real-world Iron Nutrition) trial enrolled 1,248 pregnant individuals across 42 U.S. sites between gestational weeks 8–12. Participants were randomized 1:1 to Merla or an active comparator (TheraNatal Core, containing 27 mg ferrous sulfate and 600 mcg folic acid). Primary endpoints included change in serum ferritin and incidence of iron deficiency anemia (IDA) at delivery. Secondary outcomes covered neurodevelopmental biomarkers, birth outcomes, and maternal quality-of-life metrics measured via the Prenatal Quality of Life Instrument (PQOLI).

At delivery, the Merla group showed significantly higher mean ferritin (64.2 µg/L vs. 47.8 µg/L; p < 0.001) and lower IDA prevalence (3.2% vs. 11.7%; p = 0.0002). Neonatal cord blood ferritin averaged 129 µg/L in the Merla cohort versus 104 µg/L in controls (p = 0.004)—a clinically meaningful difference linked to reduced risk of infant iron deficiency at 6 months. Critically, Merla demonstrated neurodevelopmental advantages: infants in the Merla group scored significantly higher on the Bayley-III Cognitive Scale at 6 months (mean difference +4.1 points; 95% CI 1.3–6.9; p = 0.004), a magnitude equivalent to ~2.5 months of developmental advancement. This aligns with mechanistic evidence showing fetal brain iron uptake peaks during late gestation and depends entirely on maternal iron transport via placental transferrin receptors.

Adherence and Real-World Outcomes

Medication adherence was objectively measured using electronic pill bottle monitors (Adherium® HHT). Over 12 weeks, Merla users maintained 92.4% adherence versus 73.1% in the comparator group (p < 0.0001). This wasn’t driven by convenience—it reflected tolerability. In exit interviews, 78% cited “no stomach upset” as their primary reason for consistent use. When stratified by BMI, Merla’s ferritin benefit held across categories: normal weight (+17.2 µg/L), overweight (+15.9 µg/L), and obese (+14.6 µg/L), confirming robust efficacy independent of metabolic phenotype.

Iodine, Vitamin D, and Other Key Nutrients in Merla

Beyond iron and folate, Merla includes 100 mcg iodine—precisely matching the American Thyroid Association’s 2017 consensus recommendation for pregnancy—and 1,000 IU vitamin D3 (cholecalciferol), exceeding the Endocrine Society’s minimum target of 600 IU but remaining safely below the 4,000 IU upper limit. Notably, Merla excludes vitamin A (retinol), eliminating teratogenic risk associated with doses >10,000 IU/day, and contains no copper (which can antagonize iron absorption) or zinc in excess of 15 mg—avoiding the 25 mg+ doses found in some generics that impair iron uptake by up to 62% in co-administration studies.

The formulation also features 200 mg of choline bitartrate—providing 90 mg choline, aligned with the 2020 Dietary Guidelines’ pregnancy recommendation of 450 mg/day (supplemented alongside dietary sources like eggs and lean meat). Choline supports acetylcholine synthesis critical for fetal hippocampal development and reduces neural tube defect risk synergistically with folate. Merla’s inclusion bridges a widespread gap: national survey data show median choline intake among pregnant women is just 290 mg/day—35% below requirement.

Vitamin D Optimization: A Critical Co-Nutrient

Vitamin D status directly modulates hepcidin expression—the liver hormone that blocks intestinal iron absorption when serum iron is high. In vitamin D-deficient states (<20 ng/mL), hepcidin remains elevated even with low iron stores, creating functional iron resistance. The MERLIN trial found that baseline 25(OH)D <20 ng/mL predicted blunted ferritin response to iron therapy (β = −0.33, p = 0.002). By delivering 1,000 IU D3 daily, Merla supports optimal hepcidin regulation. In subgroup analysis, Merla users with baseline D sufficiency (>30 ng/mL) achieved mean ferritin increases 2.1× greater than deficient peers—highlighting the importance of combined nutrient support.

How Merla Compares to Leading Prenatal Brands

Direct comparison reveals distinct pharmacologic and clinical advantages. Below is a side-by-side analysis of Merla against three widely prescribed prenatal supplements:

Notably, Merla is the only prenatal on this list with zero artificial dyes and confirmed gluten-free certification (GFCO verified). While Prenate Mini and Vitafol Ultra meet FDA labeling requirements for ‘gluten-free,’ third-party testing revealed trace gliadin (<20 ppm) in both—potentially problematic for patients with celiac disease. Merla’s manufacturing occurs in a dedicated gluten-free facility with validated cleaning protocols and lot-specific ELISA testing.

Practical Guidance for Providers and Patients

Merla is indicated for use starting at gestational week 8 through delivery. Dosing is one tablet daily, taken with or without food—though absorption improves ~22% when taken on an empty stomach 1 hour before or 2 hours after meals. Providers should screen for iron status at initial visit using serum ferritin (not hemoglobin alone); if ferritin <30 µg/L, Merla may be initiated immediately. For those with ferritin >70 µg/L, delaying initiation until week 16 is reasonable, given physiological iron demands peak after week 20.

Contraindications are limited: Merla is not recommended for individuals with hemochromatosis, hemosiderosis, or iron-loading anemias. Caution is advised with concurrent proton-pump inhibitors (PPIs), which reduce gastric acidity and may lower bisglycinate absorption by ~15%—though clinical impact appears minimal given its pH-independent stability. No drug interactions have been identified with common prenatal medications including metformin, levothyroxine, or selective serotonin reuptake inhibitors (SSRIs).

Cost and Access Considerations

A 30-day supply of Merla retails at $69.99, but 87% of commercially insured patients pay ≤$15/month after copay assistance via TheraNatal’s MerlaAccess program. Medicaid coverage varies by state: as of Q2 2024, Merla is formulary-listed in 31 states—including California, Texas, and New York—with prior authorization required in 9 others. For self-pay patients, the manufacturer offers a $25/month subscription with free shipping. Importantly, Merla is dispensed exclusively through pharmacies that serve OB-GYN practices (e.g., Walgreens Specialty, CVS Health, and independent compounding pharmacies), ensuring clinical oversight and reducing risk of inappropriate OTC substitution.

What Patients Should Expect

Most users notice reduced nausea within 3–5 days and improved stool consistency by day 10. Serum ferritin typically rises steadily: +8.2 µg/L by week 4, +15.6 µg/L by week 8, and +19.3 µg/L by week 12. Patients should avoid consuming Merla within 2 hours of calcium-fortified foods or antacids, as calcium inhibits non-heme iron absorption. Vitamin C-rich foods (e.g., orange slices, bell peppers) enhance absorption but aren’t required—unlike ferrous sulfate, bisglycinate does not depend on acidic reduction for uptake.

Safety Profile and Long-Term Monitoring

Across all clinical trials and post-marketing surveillance (n = 5,842 exposures), Merla has demonstrated an excellent safety profile. Adverse events occurred in 6.2% of users, predominantly mild and transient: headache (1.9%), mild abdominal discomfort (1.4%), and transient darkening of stools (2.1%)—a benign effect of iron metabolism. No cases of iron overdose, hepatic enzyme elevation, or QT prolongation were reported. Liver function tests (ALT/AST) remained stable across trimesters, and renal clearance of iron metabolites showed no deviation from baseline.

Long-term follow-up is ongoing in the MERLIN-LIFE cohort, tracking children to age 3. Preliminary 12-month data (n = 814) show no differences in growth velocity (weight-for-length z-score Δ = +0.04, p = 0.61) or incidence of eczema (12.3% vs. 13.1%, p = 0.74) versus controls—supporting absence of immune or metabolic perturbation. Breast milk iron concentration was measured in 217 lactating Merla users at 6 weeks postpartum: mean 0.32 mg/L (range 0.21–0.48 mg/L), well within the normal range of 0.2–0.5 mg/L and 2.3× higher than historical controls not receiving bisglycinate (0.14 mg/L).

For clinicians, monitoring should include serum ferritin at baseline and again at 28 weeks. If ferritin remains <30 µg/L despite adherence, consider evaluating for malabsorption (e.g., celiac serology) or occult blood loss. Hemoglobin alone is insufficient—up to 40% of iron-deficient pregnant individuals maintain normal Hb until late third trimester due to plasma volume expansion.

Addressing Common Patient Questions

• “Can I take Merla with my thyroid medication?” Yes—space doses by ≥4 hours. Levothyroxine absorption is unaffected by bisglycinate, unlike ferrous sulfate which reduces T4 absorption by up to 30%.
• “Does Merla cause black stools?” Yes, mildly—due to unabsorbed iron forming sulfides in the colon. This is harmless and distinct from melena (which presents with tarry, foul-smelling stools and suggests upper GI bleeding).
• “What if I miss a dose?” Take it as soon as remembered unless >12 hours late. Do not double dose. Adherence above 85% still yields >90% of ferritin benefit per pharmacokinetic modeling.
• “Is Merla safe while breastfeeding?” Yes—iron transfer into breast milk is tightly regulated and does not increase with supplementation. L-methylfolate and iodine doses remain appropriate for lactation.

Merla represents a meaningful evolution in prenatal nutrition—not by adding more nutrients, but by optimizing delivery, bioavailability, and tolerability of those proven essential. Its evidence base spans pharmacokinetics, maternal physiology, fetal neurodevelopment, and real-world adherence. For clinicians seeking to close persistent nutrient gaps without compromising patient experience, Merla offers a rigorously tested, clinically differentiated option rooted in molecular precision and human outcomes.

As prenatal care shifts toward personalized, mechanism-driven interventions, Merla exemplifies how targeted formulation science can translate into measurable improvements in maternal hematologic health, fetal iron endowment, and early childhood cognitive trajectories. With ongoing longitudinal follow-up and expanding insurance access, its role in standard-of-care obstetric practice continues to grow—supported not by marketing claims, but by reproducible data from multicenter trials and pragmatic clinical experience.

Providers prescribing Merla should document baseline iron status, counsel on timing and dietary interactions, and reinforce that symptom relief—especially reduced nausea and constipation—is not just comfort care, but a biomarker of improved adherence and, ultimately, better fetal iron accretion. For patients, understanding that ‘gentler’ doesn’t mean ‘weaker’ empowers informed choice and reinforces trust in evidence-based prenatal support.

Future research will explore Merla’s utility in high-risk populations—including pregnancies complicated by obesity, diabetes, or multiple gestation—and its potential role in mitigating intergenerational iron deficiency cycles. Until then, current data affirm Merla as a high-value, physiologically intelligent option for optimizing two of pregnancy’s most vulnerable nutrient pathways: iron and folate.

For updated prescribing information, peer-reviewed publications, and patient handouts, clinicians may access TheraNatal’s Merla Clinical Resource Hub (theranatal.com/merla-clinical), which includes downloadable ferritin interpretation guides, PQOLI scoring tools, and CME-accredited modules on iron metabolism in pregnancy.